Taysha Gene Therapies, Inc. (TSHA)
4.30
-0.09
(-2.05%)
USD |
NASDAQ |
Oct 07, 09:37
Taysha Gene Therapies Profit Margin (Quarterly)
Profit Margin (Quarterly) Chart
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2025 | -507.8% |
| September 30, 2025 | |
| June 30, 2025 | -1.35K% |
| March 31, 2025 | -935.2% |
| December 31, 2024 | -929.0% |
| September 30, 2024 | -1.43K% |
| June 30, 2024 | -1.88K% |
| Date | Value |
|---|---|
| March 31, 2024 | -705.4% |
| December 31, 2023 | |
| September 30, 2023 | -2.47K% |
| June 30, 2023 | -1.03K% |
| March 31, 2023 | -374.5% |
| December 31, 2022 | -2.23K% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Profit Margin (Quarterly) Benchmarks
| Altimmune, Inc. | -- |
| Protalix Biotherapeutics, Inc. | 18.98% |
| Humacyte, Inc. | -9.06K% |
| Agenus, Inc. | -1.64% |
| Amgen, Inc. | 23.59% |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | -56.94% |
| Return on Assets | -39.29% |
| Return on Invested Capital | -45.63% |
| Return on Net Operating Assets | -869.6% |